Drug intelligence / Profile preview

Atusin

Development stage: Unknown
Lead developer: Neopharm
Administration: Oral

Overview

Atusin CAP is a dietary supplement developed by Neopharm Bulgaria Ltd. It is formulated as a gastro-resistant capsule containing a distillate of four purified essential oils: eucalyptus, sweet orange, lemon, and myrtle, which are rich in 1,8-cineol, limonene, and alpha-pinene. Additionally, it includes bromelain and green Brazilian propolis. The product is being investigated in a Phase 4 clinical study for its efficacy and safety in treating acute bronchitis.

Brand names: Atusin

Beyond the preview

Go deeper on Atusin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atusin.

Explore the full profile